Table 1 –
General characteristics for patients in the overall cohort and for patients with a predicted probability of 1-yr recurrence of 20% according to our nomogram
| Paramter | Statistics | Overall population (n = 950) | Patients with predicted probability of 1-yr recurrence of >20% (n = 585) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | No NAC or AC (n = 545) | NAC (n = 242) | AC (n = 146) | NAC+AC (n = 17) | Overall | No NAC or AC (n = 346) | NAC (n = 90) | AC (n = 135) | NAC + AC (n =14) | ||
| Age at surgery (yr) | Median | 68 | 71 | 64 | 65 | 62 | 68 | 71 | 64 | 64 | 61.5 |
| IQR | 60–74 | 63–77 | 57–70 | 56–70 | 55–68 | 61–75 | 63–78 | 60–70 | 56–70 | 55–67 | |
| LNs removed (n) | Median | 15 | 15 | 16 | 16 | 20.5 | 16 | 16 | 16 | 16 | 22 |
| IQR | 9–22 | 9–22 | 10–22 | 10–240 | 14–27 | 10–24 | 10–23 | 9–22 | 10–24 | 15–25 | |
| Positive LNs (n) | Median | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 1 | 3 |
| IQR | 0–1 | 0–1 | 0–0 | 0–3 | 0–4.5 | 0–2 | 0–2 | 0–2 | 0–3 | 2–6 | |
| Race, n (%) | Caucasian | 850 (90) | 479 (88) | 229 (95) | 128 (88) | 14 (82) | 518 (89) | 307 (89) | 80 (89) | 119 (88) | 12 (86) |
| Hispanic or Latino | 69 (7) | 51 (9) | 1 (0.4) | 16 (11) | 1 (6) | 42 (7) | 26 (7) | 1 (1) | 14 (10) | 1 (7) | |
| Black | 22 (2) | 9 (2) | 9 (3.6) | 2 (1) | 2 (12) | 20 (3) | 9 (3) | 8 (9) | 2 (2) | 1 (7) | |
| Other or mixed | 9 (1) | 6 (1) | 3 (1) | 0 (0) | 0 (0) | 5 (1) | 4 (1) | 1 (1) | 0 (0) | 0 (0) | |
| Smoking status, n (%) | Never smoker | 192 (20) | 111 (20) | 55 (23) | 22 (15) | 4 (24) | 121 (21) | 76 (22) | 19 (21) | 22 (16) | 4 (29) |
| Current smoker | 215 (23) | 110 (20) | 62 (25) | 39 (27) | 4 (24) | 124 (21) | 68 (20) | 15 (17) | 38 (28) | 3 (21) | |
| Former smoker | 351 (37) | 179 (33) | 108 (45) | 57 (39) | 7 (41) | 220 (38) | 113 (33) | 50 (55) | 51 (38) | 6 (43) | |
| Unknown | 192 (20) | 145 (27) | 17 (7) | 28 (19) | 2 (11) | 120(20) | 89 (25) | 6 (7) | 24 (18) | 1 (7) | |
| CCI, n (%) | 0 | 288 (30) | 133 (25) | 100 (41) | 47 (32) | 8 (47) | 173 (29) | 85 (24) | 36 (40) | 45 (33) | 7 (50) |
| ≥1 | 567 (60) | 377 (69) | 89 (37) | 92 (63) | 9 (53) | 366 (63) | 241 (70) | 35 (39) | 83 (62) | 7 (50) | |
| Unknown | 95 (10) | 35 (6) | 53 (22) | 7 (5) | 0 (0) | 46 (8) | 20 (6) | 19 (21) | 7 (6) | 0 (0) | |
| Histology, n (%) | Pure UC | 826 (87) | 474 (87) | 206 (85) | 129 (88) | 17 (100) | 504 (86) | 292 (84) | 78 (87) | 120 (89) | 14 (100) |
| UC with DH | 124 (13) | 71 (13) | 36 (15) | 17 (12) | 0 (0) | 81 (14) | 54 (16) | 12 (13) | 15(11) | 0 (0) | |
| cT stage, n (%) | cT2 | 567 (60) | 319 (59) | 145 (60) | 91 (62) | 12 (70) | 332 (57) | 188 (54) | 48 (53) | 86 (64) | 10 (72) |
| cT3–4 | 223 (23) | 100 (18) | 91 (38) | 29 (20) | 3 (18) | 151 (26) | 80 (23) | 40 (45) | 28 (21) | 3 (2) | |
| Unknown | 160 (17) | 126 (23) | 6 (2) | 26 (18) | 2 (12) | 102 (17) | 78 (23) | 2 (2) | 21 (15) | 1 (7) | |
| pT stage, n (%) | pT0 | 96 (10) | 17 (3) | 79 (33) | 0 (0) | 0 (0) | |||||
| pT1 | 63 (7) | 43 (8) | 16 (7) | 3 (2) | 1 (6) | 3 (1) | 2 (1) | 0 (0) | 1 (1) | 0(0) | |
| pT2 | 189 (20) | 121 (22) | 42 (17) | 21 (14) | 5 (29) | 38 (6) | 17 (5) | 5 (6) | 13 (10) | 3(21) | |
| pT3 | 389 (41) | 232 (43) | 65 (27) | 84 (58) | 8 (47) | 389 (66) | 232 (67) | 65 (72) | 84 (62) | 8 (58) | |
| pT4 | 154 (16) | 94 (17) | 20 (8) | 37 (25) | 3 (18) | 154 (26) | 94 (27) | 20 (22) | 37 (27) | 3(21) | |
| pTa/pTis | 59 (6) | 38 (7) | 20 (8) | 1 (1) | 0 (0) | 1 (0.2) | 1 (0.3) | 0 (0) | 0 (0) | 0 (0) | |
| pN stage, n (%) | pN0 | 644 (68) | 379 (70) | 197 (81) | 61 (42) | 7 (41) | 298 (51) | 191 (55) | 50 (56) | 53 (39) | 4 (29) |
| pN1 | 102 (10) | 50 (9) | 20 (8) | 31 (21) | 1 (6) | 94 (16) | 47 (14) | 17 (19) | 29 (22) | 1 (7) | |
| pN2 | 160 (17) | 89 (16) | 21 (9) | 43 (30) | 7 (41) | 158 (27) | 88 (25) | 20 (22) | 43 (32) | 7 (50) | |
| pN3 | 16 (2) | 7 (1) | 1 (0.5) | 6 (4) | 2 (12) | 16 (3) | 7 (2) | 1 (1) | 6 (4) | 2 (14) | |
| pNX | 28 (3) | 20 (4) | 3 (1.5) | 5 (3) | 0 (0) | 19 (3) | 13 (4) | 2 (2) | 4 (3) | 0 (0) | |
| pTpN, n (%) | pT0–2pN0-X | 382 (40) | 207 (38) | 154 (64) | 16 (11) | 5 (29) | 25 (4) | 11 (3) | 5 (6) | 7 (5) | 2 (14) |
| pT3–4 or pN1 | 568 (60) | 338 (62) | 88 (36) | 130 (89) | 12 (71) | 560 (96) | 335 (97) | 85 (94) | 128 (95) | 12 (86) | |
| Margins status, n (%) | Negative | 866 (91) | 497 (91) | 222 (92) | 134 (92) | 13 (77) | 503 (86) | 300 (87) | 70 (78) | 123 (91) | 10 (71) |
| Positive | 84 (9) | 48 (9) | 20 (8) | 12 (8) | 4 (23) | 82 (14) | 46 (13) | 20 (22) | 12 (9) | 4 (29) | |
| NAC, n (%) | No | 691 (73) | 545 (100) | 0 (0) | 146 (100) | 0 (0) | 481 (82) | 346 (100) | 0 (0) | 135 (100) | 0 (0) |
| Yes | 259 (27) | 0 (0) | 242 (100) | 0 (0) | 17 (100) | 104(18) | 0 (0) | 90 (100) | 0 (0) | 14(100) | |
| NAC platinum regimen, n (%) | Carboplatin | 22 (2) | 0 (0) | 20 (8) | 0 (0) | 2 (12) | 15 (3) | 0 (0) | 13 (15) | 0 (0) | 2 (14) |
| Cisplatin | 214 (23) | 0 (0) | 203 (84) | 0 (0) | 11 (65) | 76 (13) | 0 (0) | 66 (73) | 0 (0) | 10 (72) | |
| No NAC | 691 (73) | 545 (100) | 0 (0) | 146 (100) | 0 (0) | 481 (82) | 346 (100) | 0 (0) | 135 (100) | 0 (0) | |
| Unknown regimen | 23 (2) | 0 (0) | 19 (8) | 0 (0) | 4 (23) | 13 (2) | 0 (0) | 11 (12) | 0 (0) | 2 (14) | |
| AC, n (%) | No | 787 (83) | 545 (100) | 242 (100) | 0 (0) | 0 (0) | 436 (75) | 346 (100) | 90 (100) | 0 (0) | 0 (0) |
| Yes | 163 (17) | 0 (0) | 0 (0) | 146 (100) | 17 (100) | 149 (25) | 0 (0) | 0 (0) | 135 (100) | 14 (100) | |
| AC platinum regimen, n (%) | Carboplatin | 20 (2) | 0 (0) | 0 (0) | 18 (12) | 2 (12) | 19 (3) | 0 (0) | 0 (0) | 17 (13) | 2 (14) |
| Cisplatin | 83 (9) | 0 (0) | 0 (0) | 73 (50) | 10 (59) | 79 (13) | 0 (0) | 0 (0) | 70 (52) | 9 (64) | |
| No AC | 787 (83) | 545 (100) | 242 (100) | 0 (0) | 0 (0) | 436 (75) | 346 (100) | 90 (100) | 0 (0) | 0 (0) | |
| Unknown regimen | 60 (6) | 0 (0) | 0 (0) | 55 (38) | 5 (29) | 51 (9) | 0 (0) | 0 (0) | 48 (35) | 3 (22) | |
AC = adjuvant chemotherapy; CCI = Charlson comorbidity index; DH = divergent histology; IQR: interquartile range; LN = lymph node; NAC = neoadjuvant chemotherapy; UC = urothelial carcinoma.